Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway

Life Sciences

Volumn 88, Issue 1-2, 2011, Pages 43-49

  Sato, Youichi ^a   Koshioka, Sakura ^a   Kirino, Yasushi ^a   Kamimoto, Takayuki ^a   Kawazoe, Kazuyoshi ^a   Abe, Shinji ^a   Minakuchi, Kazuo ^a   Nakahori, Yutaka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Diabetes; DPP4 deficient; Dyslipidemia; Steroid metabolism; Streptozotocin

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; CYTOCHROME P450 51A1; DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA; PROTEIN; STEROL 14ALPHA DEMETHYLASE; STEROL C4 METHYL OXIDASE LIKE PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DYSLIPIDEMIA; HUMAN; HUMAN CELL; LIPID METABOLISM; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STEROIDOGENESIS; UNINDEXED SEQUENCE; WILD TYPE;

ANIMALS; CELL LINE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE 4; DYSLIPIDEMIAS; ESTRADIOL DEHYDROGENASES; HUMANS; LIPID METABOLISM; LIVER; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROL 14-DEMETHYLASE; STREPTOZOCIN;

RATTUS;

EID: 78650522810     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.10.019     Document Type: Article

References (33)

1. J. Brannian, K. Eyster, M. Greenway, C. Henriksen, K. Teslaa, and M. Diggins Progressive obesity leads to altered ovarian gene expression in the Lethal Yellow mouse: a microarray study J Ovarian Res 2 2009 10
2. C.P. Cannon Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications Am J Cardiol 102 2008 5L 9L
3. R.A. Coleman, T.M. Lewin, C.G. Van Horn, and M.R. Gonzalez-Baró Do long-chain acyl-CoA synthetases regulate fatty acid entry into synthetic versus degradative pathways? J Nutr 132 2002 2123 2126
4. O.B. Crofford Diabetes control and complications Annu Rev Med 46 1995 267 279
5. E.D. Crook, A. Thallapureddy, S. Migdal, J.M. Flack, E.L. Greene, and A. Salahudeen Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 325 2003 340 348
6. R.A. DeFronzo Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 131 1999 281 303
7. R.H. Erickson, Y. Suzuki, A. Sedlmayer, and Y.S. Kim Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme J Biol Chem 267 1992 21623 21629
8. H.N. Ginsberg Insulin resistance and cardiovascular disease J Clin Invest 106 2000 453 458
9. Glaser C., Heinrich J., and Koletzko B. Role of FADS1 and FADS2 polymorphisms in polyunsaturated fatty acid metabolism Metabolism 59 2010 993 999
10. M.R. Gonzalez-Baró, T.M. Lewin, and R.A. Coleman Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action Am J Physiol Gastrointest Liver Physiol 292 2007 1195 1199
11. B.D. Green, P.R. Flatt, and C.J. Bailey Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes Diab Vasc Dis Res 3 2006 159 165
12. D. Hinnen, L.L. Nielsen, A. Waninger, and P. Kushner Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes J Am Board Fam Med 6 2006 612 620
13. J.J. Holst, and J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab 287 2004 E199 E206
14. J.J. Holst Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005 Diabetologia 49 2006 253 260
15. R. Iakoubov, A. Izzo, A. Yeung, C.I. Whiteside, and P.L. Brubaker Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells Endocrinology 148 2007 1089 1098
16. D.M. Kendall, D. Kim, and D. Maggs Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes Diabetes Technol Ther 3 2006 385 396
17. Y. Kirino, Y. Sato, T. Kamimoto, K. Kawazoe, K. Minakuchi, and Y. Nakahori Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats J Endocrinol 200 2009 53 61
18. E. Lattka, T. Illig, J. Heinrich, and B. Koletzko Do FADS genotypes enhance our knowledge about fatty acid related phenotypes? Clin Nutr 29 2010 277 287
19. S.X. Lin, R. Shi, W. Qiu, A. Azzi, D.W. Zhu, and H.A. Dabbagh Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5 Mol Cell Endocrinol 248 2006 38 46
20. Y. Liu, Z.X. Yao, and V. Papadopoulos Cytochrome P450 17alpha hydroxylase/17, 20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells Mol Endocrinol 19 2005 1918 1931
21. W.J. Lu, Q. Yang, W. Sun, S.C. Woods, D. D'Alessio, and P. Tso Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose Am J Physiol Gastrointest Liver Physiol 294 2008 G1130 G1138
22. S. Mäkimattila, K. Nikkilä, and H. Yki-Järvinen Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus Diabetologia 42 1999 406 412
23. Y. Masuda, H. Itabe, M. Odaki, K. Hama, Y. Fujimoto, and M. Mori ADRP/adipophilin is degraded through the proteasome-dependent pathway during regression of lipid-storing cells J Lipid Res 47 2006 87 98
24. R. Mentlein Dipeptidyl-peptidase IV (CD26) role in the inactivation of regulatory peptides Regul Pept 85 1999 9 24
25. H. Mitani, M. Takimoto, T.E. Hughes, and M. Kimura Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity Jpn J Pharmacol 88 2002 442 450
26. L.L. Nielsen Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes Drug Discov Today 10 2005 703 710
27. A. Rosanoff, and M.S. Seelig Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals J Am Coll Nutr 23 2004 501 505
28. C.S. Song, J.M. Kim, A.K. Roy, and B. Chatterjee Structure and regulation of the senescence marker protein 2 gene promoter Biochemistry 29 1990 542 551
29. B.T. Srinivasan, J. Jarvis, K. Khunti, and M.J. Davies Recent advances in the management of type 2 diabetes mellitus: a review Postgrad Med J 996 2008 524 531
30. Y.Q. Su, K. Sugiura, K. Wigglesworth, M.J. O'Brien, J.P. Affourtit, and S.A. Pangas Oocyte regulation of metabolic cooperativity between mouse cumulus cells and oocytes: BMP15 and GDF9 control cholesterol biosynthesis in cumulus cells Development 135 2008 111 121
31. N.L. Thompson, D.C. Hixson, H. Callanan, M. Panzica, D. Flanagan, and R.A. Faris A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model Biochem J 273 1991 497 502
32. N. Yasuda, T. Nagakura, K. Yamazaki, T. Inoue, and I. Tanaka Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats Life Sci 71 2002 227 238
33. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787